Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,531 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of Olanzapine in Addition to Standard Triplet Antiemetic Therapy for Cisplatin-Based Chemotherapy: A Secondary Analysis of the J-FORCE Randomized Clinical Trial.
Abe M, Yamaguchi T, Fujita Y, Nishimura T, Kitagawa K, Inui N, Hirano K, Sakata Y, Iihara H, Shibuya Y, Suzuki K, Shibata K, Hori K, Daga H, Nakayama T, Sakata Y, Takahashi TY, Zenda S, Hashimoto H. Abe M, et al. Among authors: shibata k. JAMA Netw Open. 2023 May 1;6(5):e2310894. doi: 10.1001/jamanetworkopen.2023.10894. JAMA Netw Open. 2023. PMID: 37129897 Free PMC article. Clinical Trial.
Phase II study of combination chemotherapy with gemcitabine and irinotecan in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens.
Ohyanagi F, Taguchi F, Horai T, Kasahara K, Takeda Y, Shibata K, Shirosaki H, Nishio M. Ohyanagi F, et al. Among authors: shibata k. Jpn J Clin Oncol. 2006 Sep;36(9):547-51. doi: 10.1093/jjco/hyl062. Epub 2006 Jul 26. Jpn J Clin Oncol. 2006. PMID: 16870693 Clinical Trial.
Prospective analysis of factors precluding the initiation of durvalumab from an interim analysis of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study).
Tanzawa S, Makiguchi T, Tasaka S, Inaba M, Ochiai R, Nakamura J, Inoue K, Kishikawa T, Nakashima M, Fujiwara K, Kohyama T, Ishida H, Kuyama S, Miyazawa N, Nakamura T, Miyawaki H, Oda N, Ishikawa N, Morinaga R, Kusaka K, Miyamoto Y, Yokoyama T, Matsumoto C, Tsuda T, Ushijima S, Shibata K, Shibayama T, Bessho A, Kaira K, Misumi T, Shiraishi K, Matsutani N, Seki N. Tanzawa S, et al. Among authors: shibata k. Ther Adv Med Oncol. 2022 Jul 29;14:17588359221116603. doi: 10.1177/17588359221116603. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35923924 Free PMC article.
Phase II study of sequential triplet chemotherapy, irinotecan and cisplatin followed by amrubicin, in patients with extensive-stage small cell lung cancer: West Japan Thoracic Oncology Group Study 0301.
Kobayashi M, Matsui K, Iwamoto Y, Ebi N, Oizumi S, Takeda K, Sawa T, Shibata K, Saka H, Imamura F, Seki N, Saito H, Goto I, Nakagawa K; West Japan Oncology Group. Kobayashi M, et al. Among authors: shibata k. J Thorac Oncol. 2010 Jul;5(7):1075-80. doi: 10.1097/JTO.0b013e3181dd1591. J Thorac Oncol. 2010. PMID: 20479694 Free article. Clinical Trial.
A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study).
Tanzawa S, Ushijima S, Shibata K, Shibayama T, Bessho A, Kaira K, Misumi T, Shiraishi K, Matsutani N, Tanaka H, Inaba M, Haruyama T, Nakamura J, Kishikawa T, Nakashima M, Iwasa K, Fujiwara K, Kohyama T, Kuyama S, Miyazawa N, Nakamura T, Miyawaki H, Ishida H, Oda N, Ishikawa N, Morinaga R, Kusaka K, Fujimoto N, Yokoyama T, Gemba K, Tsuda T, Nakagawa H, Ono H, Shimizu T, Nakamura M, Kusumoto S, Hayashi R, Shirasaki H, Ochi N, Aoe K, Kanaji N, Kashiwabara K, Inoue H, Seki N. Tanzawa S, et al. Among authors: shibata k. Ther Adv Med Oncol. 2021 Feb 27;13:1758835921998588. doi: 10.1177/1758835921998588. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 33717228 Free PMC article.
Phase II trial of amrubicin for second-line treatment of advanced non-small cell lung cancer: results of the West Japan Thoracic Oncology Group trial (WJTOG0401).
Kaneda H, Okamoto I, Hayashi H, Yoshioka H, Miyazaki M, Kudoh S, Kimura T, Sugiura T, Sawa T, Takeda K, Iwamoto Y, Satouchi M, Akita K, Saito H, Goto I, Shibata K, Fukuoka M, Nakagawa K; West Japan Thoracic Oncology Group. Kaneda H, et al. Among authors: shibata k. J Thorac Oncol. 2010 Jan;5(1):105-9. doi: 10.1097/JTO.0b013e3181c07c6c. J Thorac Oncol. 2010. PMID: 19884859 Free article. Clinical Trial.
Long-Term Survival of Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor Monotherapy in Real-World Settings.
Yoneda T, Sone T, Koba H, Shibata K, Suzuki J, Tani M, Nishitsuji M, Nishi K, Kobayashi T, Shirasaki H, Araya T, Kita T, Kase K, Yamamura K, Terada N, Nishikawa S, Tambo Y, Kimura H, Kasahara K. Yoneda T, et al. Among authors: shibata k. Clin Lung Cancer. 2022 Sep;23(6):467-476. doi: 10.1016/j.cllc.2022.03.008. Epub 2022 May 1. Clin Lung Cancer. 2022. PMID: 35618628
2,531 results